BlackRock, Inc. 13D and 13G filings for Immuneering Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-05 12:21 pm Sale | 2024-03-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,377,120 4.700% | -720,286 (-34.34%) | Filing |
| 2024-01-26 4:23 pm Purchase | 2023-12-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 2,097,406 7.200% | 760,970 (+56.94%) | Filing |
| 2023-05-05 11:52 am Sale | 2023-04-30 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,336,436 4.600% | -11,948 (-0.89%) | Filing |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,348,384 5.100% | -367,786 (-21.43%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Immuneering Corporation IMRX | BlackRock Inc. BLK | 1,716,170 6.600% | 1,716,170 (New Position) | Filing |